|Table of Contents|

Advances in preclinical model of cervical cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 04
Page:
669-675
Research Field:
Publishing date:

Info

Title:
Advances in preclinical model of cervical cancer
Author(s):
CHEN Yuanjing1; LIU Xiaofeng1; LI Wen2; LUO Renjie1; WANG Dan1; ZHANG Wenyan1; LIU Huiling2
1.The First Clinical Medical College,Gansu University of Traditional Chinese Medicine,Gansu Lanzhou 730000,China;2.Department of Gynecology,Gansu Provincial Hospital,Gansu Lanzhou 730000,China.
Keywords:
cervical cancer; patient-derived xenografts model; genetically engineered mouse model; organoid model
PACS:
R737.33
DOI:
10.3969/j.issn.1672-4992.2025.04.019
Abstract:
Cervical cancer is the fourth most common cancer affecting women worldwide after breast cancer,lung cancer and colorectal cancer.Although it is a preventable cancer,the high incidence and mortality rates reflect that it is a major reproductive health problem.At present,the recurrence and metastasis rate of clinical cervical cancer patients after drug treatment,surgical treatment and chemotherapy is still high.Animal model can simulate the development characteristics of cervical cancer and is an important tool for the prevention and treatment of cervical cancer.This paper introduces three animal models that have been widely studied at present,including patient-derived xenografts (PDX) model,genetically engineered mouse (GEM) model and organoid model.The types of mice used in each cervical cancer animal model,construction methods,research progress,advantages and disadvantages were described in detail,in order to provide theoretical basis for the construction of cervical cancer animal model.At the same time,it is predicted that the combined application of multiple models can make tumor research more accurate and convenient,and even organoid models will become a future trend to replace ordinary animal models.

References:

［1］ BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(3):229-263.
[2] KHAIRKHAH N,BOLHASSANI A,NAJAFIPOUR R.Current and future direction in treatment of HPV-related cervical disease［J］.J Mol Med (Berl),2022,100(6):829-845.
[3] KUSAKABE M,TAGUCHI A,SONE K,et al.Carcinogenesis and management of human papillomavirus-associated cervical cancer［J］.Int J Clin Oncol,2023,28(8):965-974.
[4] JIN J,YOSHIMURA K,SEWASTJANOW-SILVA M,et al.Challenges and prospects of patient-derived xenografts for cancer research［J］.Cancers (Basel),2023,15(17):4352.
[5] GJERSTORFF MF,TRAYNOR S,GAMMELGAARD OL,et al.PDX models:a versatile tool for studying the role of myeloid-derived suppressor cells in breast cancer［J］.Cancers (Basel),2022,14(24)：6153.
[6] STEINKAMP MP,LAGUTINA I,BRAYER KJ,et al.Humanized patient-derived xenograft models of disseminated ovarian cancer recapitulate key aspects of the tumor immune environment within the peritoneal cavity［J］.Cancer Res Commun,2023,3(2):309-324.
[7] LIU W,CUI Y,ZHENG X,et al.Application status and future prospects of the PDX model in lung cancer［J］.Front Oncol,2023,13:1098581.
[8] 闫克敏，孙佳，王娇娇，等.PDX模型在恶性肿瘤中应用的研究进展［J］.现代肿瘤医学，2019,27（09）：1629-1634. YAN Kemin,SUN Jia,WANG Jiaojiao,et al.Research progress of PDX model in application of malignant tumors［J］.Modern Oncology,2019,27（09）：1629-1634.
[9] ABDOLAHI S,GHAZVINIAN Z,MUHAMMADNEJAD S,et al.Patient-derived xenograft (PDX) models,applications and challenges in cancer research［J］.J Transl Med,2022,20(1):206.
[10] CHOI YY,LEE JE,KIM H,et al.Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer［J］.Sci Rep,2016,6:22172.
[11] ZHANG Y,YANG Y,ZAN L,et al.Preparation and application of patient-derived xenograft mice model of colorectal cancer［J］.Iran J Basic Med Sci,2023,26(2):248-254.
[12] ZENG M,RUAN Z,TANG J,et al.Generation,evolution,interfering factors,applications,and challenges of patient-derived xenograft models in immunodeficient mice［J］.Cancer Cell Int,2023,23(1):120.
[13] PAN B,WEI X,XU X.Patient-derived xenograft models in hepatopancreatobiliary cancer［J］.Cancer Cell Int,2022,22(1):41.
[14] 付后卫,何顺朋,施祥德,等.转移瘤动物模型的构建及其检测方法［J］.中华全科医学,2017,15(01):142-146. FU Houwei,HE Shunpeng,SHI Xiangde,et al.Construction of animal model of metastatic tumor and its detection method［J］.Chinese General Practice,2017,15(01):142-146.
[15] ZOU S,YE M,ZHANG JA,et al.Establishment and genetically characterization of patient-derived xenograft models of cervical cancer［J］.BMC Med Genomics,2022,15(1):191.
[16] LIU L,WU M,HUANG A,et al.Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient's response to conventional and novel therapies［J］.J Transl Med,2023,21(1):611.
[17] MATOSSIAN MD,CHANG T,WRIGHT MK,et al.In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types［J］.Clin Transl Oncol,2022,24(1):127-144.
[18] 刘张驰,王娟,陈旭.人源肿瘤异种移植小鼠模型研究进展［J］.中国实验动物学报,2023,31(03):374-381. LIU Zhangchi,WANG Juan,CHEN Xu.Research progress of human tumor xenotrans -plantation mouse model［J］.Chinese Journal of Experimental Animals,2023,31(03):374-381.
[19] YIN Z,MASWIKITI EP,LIU Q,et al.Current research developments of patient-derived tumour xenograft models (Review)［J］.Exp Ther Med,2021,22(5):1206.
[20] SHIN HY,LEE EJ,YANG W,et al.Identification of prognostic markers of gynecologic cancers utilizing patient-derived xenograft mouse models［J］.Cancers (Basel),2022,14(3):829.
[21] TAN YQ,CHIOU YS,GUO H,et al.Vertical pathway inhibition of receptor tyrosine kinases and BAD with synergistic efficacy in triple negative breast cancer［J］.NPJ Precis Oncol,2024,8(1):8.
[22] BAIETTI MF,LEUCCI E.Humanized mouse models for anti-cancer therapy［J］.Methods Cell Biol,2024,183:317-333.
[23] SERRANO A,WEBER T,BERTHELET J,et al.Experimental and spontaneous metastasis assays can result in divergence in clonal architecture［J］.Commun Biol,2023,6(1):821.
[24] WANG W,LI Y,LIN K,et al.Progress in building clinically relevant patient-derived tumor xenograft models for cancer research［J］.Animal Model Exp Med,2023,6(5):381-398.
[25] KAUSHAL JB,TAKKAR S,BATRA SK,et al.Diverse landscape of genetically engineered mouse models:Genomic and molecular insights into prostate cancer［J］.Cancer Lett,2024,593:216954.
[26] WEFERS B,WURST W,KüHN R.Gene editing in mouse zygotes using the CRISPR/Cas9 system［J］.Methods Mol Biol,2023,2631:207-230.
[27] 许瀚林,陈建军,赵飞,等.临床前肿瘤模型的建立和应用进展［J］.中国新药杂志,2023,32(10):1021-1027. XU Hanlin,CHEN Jianjun,ZHAO Fei,et al.Establishment and application of preclinical tumor model［J］.Chinese Journal of New Drugs,2023,32(10):1021-1027.
[28] SONG HK,HWANG DY.Use of C57BL/6N mice on the variety of immunological researches［J］.Lab Anim Res,2017,33(2):119-123.
[29] GAO C,WU P,YU L,et al.The application of CRISPR/Cas9 system in cervical carcinogenesis［J］.Cancer Gene Ther,2022,29(5):466-474.
[30] LING K,DOU Y,YANG N,et al.Genome editing mRNA nanotherapies inhibit cervical cancer progression and regulate the immunosuppressive microenvironment for adoptive T-cell therapy［J］.J Control Release,2023,360:496-513.
[31] FERREIRA T,NASCIMENTO-GONCALVES E,MACEDO S,et al.Toxicological and anti-tumor effects of a linden extract (Tilia platyphyllos Scop.) in a HPV16-transgenic mouse model［J］.Food Funct,2021,12(9):4005-4014.
[32] HENKLE TR,LAM B,KUNG YJ,et al.Development of a novel mouse model of spontaneous high-risk HPVE6/E7-expressing carcinoma in the cervicovaginal tract［J］.Cancer Res,2021,81(17):4560-4569.
[33] YUAN J,LI X,YU S.Cancer organoid co-culture model system:Novel approach to guide precision medicine［J］.Front Immunol,2022,13:1061388.
[34] YAN HHN,CHAN AS,LAI FP,et al.Organoid cultures for cancer modeling［J］.Cell Stem Cell,2023,30(7):917-937.
[35] ZHOU C,WU Y,WANG Z,et al.Standardization of organoid culture in cancer research［J］.Cancer Med,2023,12(13):14375-14386.
[36] KUTLE I,POLTEN R,HACHENBERG J,et al.Tumor organoid and spheroid models for cervical cancer［J］.Cancers (Basel),2023,15(9):2518.
[37] XU H,JIAO D,LIU A,et al.Tumor organoids:applications in cancer modeling and potentials in precision medicine［J］.J Hematol Oncol,2022,15(1):58.
[38] MARU Y,TANAKA N,EBISAWA K,et al.Establishment and characterization of patient-derived organoids from a young patient with cervical clear cell carcinoma［J］.Cancer Sci,2019,110(9):2992-3005.
[39] LHMUSSAAR K,OKA R,ESPEJO VALLE-INCLAN J,et al.Patient-derived organoids model cervical tissue dynamics and viral oncogenesis in cervical cancer［J］.Cell Stem Cell,2021,28(8):1380-1396.
[40] SEOL HS,OH JH,CHOI E,et al.Preclinical investigation of patient-derived cervical cancer organoids for precision medicine［J］.J Gynecol Oncol,2023,34(3):e35.
[41] HUANG H,PAN Y,HUANG J,et al.Patient-derived organoids as personalized avatars and a potential immunotherapy model in cervical cancer［J］.iScience,2023,26(11):108198.
[42] KUSAKABE M,TAGUCHI A,TANIKAWA M,et al.Application of organoid culture from HPV18-positive small cell carcinoma of the uterine cervix for precision medicine［J］.Cancer Med,2023,12(7):8476-8489.
[43] HU B,WANG R,WU D,et al.A promising new model:establishment of patient-derived organoid models covering HPV-related cervical pre-cancerous lesions and their cancers［J］.Adv Sci (Weinh),2024,11(12):e2302340.

Memo

Memo:
National Natural Science Foundation of China(No.82260557）；国家自然科学基金（编号：82260557）；甘肃省兰州市科技计划项目（编号：2023-ZD-21）
Last Update: 1900-01-01